Akeso, Inc.

9926

KYG0146B1032

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 10:33:26 2024-04-28 pm EDT			5-day change	1st Jan Change
49.1 ^HKD	+0.82%		+10.71%	+5.82%

Apr. 24	Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	MT
Apr. 24	National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	CI

Akeso, Inc. Announces Resignation of Xi Xiaojie as Chief Financial Officer, May 3, 2023

April 28, 2023 at 10:31 am EDT

Akeso, Inc. announced that Mr. XI Xiaojie has tendered his resignation as chief financial officer of the Company with effect from May 3, 2023 as a result of personal career development.

Latest news about Akeso, Inc.

Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	Apr. 24	MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	Apr. 23	CI
Akeso to Raise Over HK$1 Billion Via Share Sale	Mar. 22	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	Mar. 18	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	Mar. 06	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	Mar. 05	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 04	CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	Feb. 23	MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	Feb. 15	RE
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	Feb. 08	MT
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	Jan. 23	CI
Akeso, Inc. Announces Innovative Clinical Development Roadmap	Jan. 08	CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	Jan. 04	MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer	Jan. 04	CI
Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023	Dec. 15	CI
Akeso Publishes Results from Three Investigator-Initiated Trials	Dec. 05	CI
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate its Innovation Globalization Strategy	Nov. 28	CI
Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival for First-Line Treatment of Recurrent/Metastatic Cervical Cancer	Nov. 27	CI
Akeso's Phase 3 Trial for Cervical Cancer Attains Progression-Free Survival	Nov. 22	MT
Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer	Nov. 22	CI
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)	Nov. 07	CI
Akeso's Clinical Trial for Gastroesophageal Cancer Treatment Achieves Primary Outcomes	Nov. 06	MT
Akeso, Inc. Announces A Phase III Trial of Cadonilimab in Combination with Chemotherapy as First Line Treatment for GASTRIC or Gastesophageal Junction Adenocarcinoma (GC/GEJC) Reaches Primary Endpoint of Overall Survival	Nov. 06	CI
Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody	23-10-30	CI

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Akeso, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.08 CNY

Average target price

55.44 CNY

Spread / Average Target

+22.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AKESO, INC.	+5.82%	5.39B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Akeso, Inc. Announces Resignation of Xi Xiaojie as Chief Financial Officer, May 3, 2023

Latest news about Akeso, Inc.

Chart Akeso, Inc.

Company Profile

Income Statement Evolution

Ratings for Akeso, Inc.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs